


Janus Henderson

Janus Henderson Biotechnology EUR Acc

LU2441283277

21-05-2026

FM



Investment objective

Fees

| | |
|---------------------------|---|
| Entry fee | -->Tarievenkaart / Cost information sheet |
| Exit charges | -->Tarievenkaart / Cost information sheet |
| Estimated ongoing charges | 1,23% |

Dividend

| | |
|-----------------|----|
| Dividend paying | No |
|-----------------|----|

Quote

| | |
|------------|------------|
| Quote | €28,16 |
| Quote date | 20-05-2026 |

Performance in EUR

| | |
|--------------------------|------------|
| Date | 20-05-2026 |
| This year | 0,86% |
| 1 week | -3,76% |
| 1 month | -6,51% |
| 3 months | -0,39% |
| 6 months | 3,80% |
| 1 year | 65,45% |
| 3 years (annualised) | 18,44% |
| 5 years (annualised) | - |
| Since start (annualised) | 20,05% |

Indicators


| | |
|--------------------------|--------|
| Standard deviation (3yr) | 24,00% |
| Share ratio (3yr) | 0,81 |
| Beta (3yr) | - |
| Alpha (3yr) | - |
| Tracking error (3yr) | - |


Top 10 holdings (31-03-2026)

| | |
|--|--------|
| Praxis Precision Medicines Inc Ordinary Shares | 6,39 % |
| Revolution Medicines Inc Ordinary Shares | 4,59 % |
| BridgeBio Pharma Inc | 4,34 % |
| argenx SE ADR | 3,98 % |
| Vertex Pharmaceuticals Inc | 3,81 % |
| United Therapeutics Corp | 3,80 % |
| Gilead Sciences Inc | 3,77 % |
| PTC Therapeutics Inc | 3,31 % |
| Regeneron Pharmaceuticals Inc | 3,30 % |
| Ascendis Pharma AS ADR | 3,29 % |

?>

Characteristic

| | |
|-----------------------------|---|
| Asset Manager | Janus Henderson |
| Asset class | Equities |
| Investment category | Equities - Healthcare |
| Active/Passive | Active |
| Fund code | 212809 |
| Fund code fractional orders | - |
| Fund manager name | Daniel Lyons Agustin Mohedas Andy Acker |
| ISIN | LU2441283277 |
| Sustainable Classification | Art. 8, ESG integration |
| Sustainability Rating |  |
| Domicile | Luxembourg |
| Currency | EUR |
| Fund size (mio) | 1.434,63 (20-05-2026) |
| Cut-off time | - |
| Execution date | - |
| Inception date | 25-02-2022 |
| Benchmark | NASDAQ Biotechnology TR |
| Minimum investment amount | - |
| Assortiment | Self Directed Investing Plus, Investment advice |



- United Kingdom
- North America
- Developed Markets Europe

General Disclaimer

The information provided in this document has been drafted by ABN AMRO Bank N.V

About ABN AMRO

ABN AMRO Bank N.V. has its registered office at Gustav Mahlerlaan 10, 1082 PP Amsterdam (the Netherlands). Telephone: 0900 - 0024*. Internet: abnamro.nl ABN AMRO Bank N.V. holds a banking licence from De Nederlandsche Bank N.V. (the Dutch central bank) and is included in the register of the Autoriteit Financiële Markten (AFM - Authority for the Financial Markets) under number 12000004. ABN AMRO Bank N.V. is entered in the Trade Register of the Amsterdam Chamber of Commerce under number 34334259. The VAT identification number of ABN AMRO Bank N.V. is NL8206.46.660B01.

US Securities Law Disclaimer

ABN AMRO Bank N.V. ('ABN AMRO') is not a registered broker-dealer under the U.S. Securities Exchange Act of 1934, as amended (the '1934 Act') and under applicable state laws in the United States. In addition, ABN AMRO is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the 'Advisers Act' and together with the 1934 Act, the 'Acts'), and under applicable state laws in the United States. Accordingly, absent specific exemption under the Acts, any brokerage and investment advisory services provided by ABN AMRO, including (without limitation) the investment products and investment services described herein are not intended for U.S. persons. Neither this document, nor any copy thereof may be sent to or taken into the United States or distributed in the United States or to a US person. Without limiting the generality of the foregoing, the offering, sale and/or distribution of the investment products or investment services described herein is not intended in any jurisdiction to any person to whom it is unlawful to make such an offer, sale and/or distribution. Persons into whose possession this document or any copy thereof may come, must inform themselves about, and observe, any legal restrictions on the distribution of this document and the offering, sale and/or distribution of the investment products and investment services described herein. ABN AMRO cannot be held responsible for any damages or losses that occur from transactions and/or services in defiance with the restrictions aforementioned.

* Call charges: for this call you pay your usual call charges set by your telephone provider